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Abstract: Animal-derived antivenoms are the only specific therapies currently available for
the treatment of snake envenoming, but these products have a number of limitations associated with
their efficacy, safety and affordability for use in tropical snakebite victims. Small molecule drugs
and drug candidates are regarded as promising alternatives for filling the critical therapeutic gap
between snake envenoming and effective treatment. In this study, by using an advanced analytical
technique that combines chromatography, mass spectrometry and bioassaying, we investigated
the effect of several small molecule inhibitors that target phospholipase A2 (varespladib) and snake
venom metalloproteinase (marimastat, dimercaprol and DMPS) toxin families on inhibiting
the activities of coagulopathic toxins found in Viperinae snake venoms. The venoms of Echis carinatus,
Echis ocellatus, Daboia russelii and Bitis arietans, which are known for their potent haemotoxicities,
were fractionated in high resolution onto 384-well plates using liquid chromatography followed
by coagulopathic bioassaying of the obtained fractions. Bioassay activities were correlated to
parallel recorded mass spectrometric and proteomics data to assign the venom toxins responsible for
coagulopathic activity and assess which of these toxins could be neutralized by the inhibitors under
investigation. Our results showed that the phospholipase A2-inhibitor varespladib neutralized the vast
majority of anticoagulation activities found across all of the tested snake venoms. Of the snake
venom metalloproteinase inhibitors, marimastat demonstrated impressive neutralization of the
procoagulation activities detected in all of the tested venoms, whereas dimercaprol and DMPS could
only partially neutralize these activities at the doses tested. Our results provide additional support for
the concept that combinations of small molecules, particularly the combination of varespladib with
marimastat, serve as a drug-repurposing opportunity to develop new broad-spectrum inhibitor-based
therapies for snakebite envenoming.
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1. Introduction
Bites by venomous snakes cause 81,000–138,000 deaths per annum, with the majority occurring in
the rural resource-poor regions of the tropics and sub-tropics [1]. The venomous snakes responsible
for the vast majority of severe envenomings are members of the Viperidae and Elapidae families [2,3].
Elapid snakes have venoms that are highly abundant in neurotoxins that disable muscle contraction
and cause neuromuscular paralysis [1,4]. Contrastingly, viper venoms typically contain numerous
proteins that disrupt the functioning of the coagulation cascade, the hemostatic system and tissue
integrity [4,5]. Envenomings caused by these snakes can cause prominent local effects including
necrosis, hemorrhage, edema and pain, and often result in permanent disabilities in survivors [6,7].
One of the most common but serious pathological effects of systemic viper envenoming is coagulopathy,
which renders snakebite victims vulnerable to suffering lethal internal hemorrhages [8]. Venom induced
coagulopathy following bites by viperid snakes is predominately the result of the synergistic
action of venom enzymes, such as phospholipases A2 (PLA2s), snake venom serine proteinases
(SVSPs) and snake venom metalloproteinases (SVMPs) [9–11]. PLA2s can prevent blood clotting via
anticoagulant effects. Enzymatic PLA2s function by hydrolyzing glycerophospholipids at the sn-2
position of the glycerol backbone releasing lysophospholipids and fatty acids [12]. SVSPs can
proteolytically degrade fibrinogen and release bradykinins from plasma kininogens [13,14]. SVMPs act
on various clotting factors to stimulate consumption coagulopathy and can also degrade capillary
basement membranes, thereby increasing vascular permeability and causing leakage [10,15,16].
These toxins can therefore work synergistically to cause systemic hemorrhage and coagulopathy.
The only specific therapies currently available for treating snake envenoming are animal-derived
antivenoms. Consisting of immunoglobulins purified from hyperimmunized ovine or equine
plasma/serum, these products save thousands of lives each year, but are associated with a number
of therapeutic challenges, including limited cross-snake species efficacies, poor safety profiles and, for
many snakebite victims residing in remote rural areas in developing countries, unacceptable issues
with affordability and accessibility [17]. Small molecule toxin inhibitors are regarded as promising
candidates for the development of affordable broad-spectrum snakebite treatments, as these can block
the enzymatic activities of venoms [18–20]. Varespladib, an indole-based nonspecific pan-secretory
PLA2 inhibitor has been studied extensively for repurposing for snakebite. Having originally
been investigated in Phase II and III clinical trials for treating septic shock, coronary heart disease
and sickle cell disease-induced acute chest syndrome [21,22], varespladib has since been shown to
be highly potent in suppressing venom-induced PLA2 activity, both in vitro and in vivo in murine
models [23]. Varespladib shows great promise against neurotoxic elapid snake venoms and has
been shown to prevent lethality in murine in vivo models of envenoming [24], but is seemingly also
capable of inhibiting certain myotoxic and coagulotoxic symptoms induced by snake venoms [25,26].
Moreover, varespladib has been demonstrated to inhibit the anticoagulant activity of Pseudechis australis
snake venom, which was not neutralized by its currently used antivenom [27].
A number of other small molecules have shown promise for repurposing to inhibit SVMP venom
toxins. Marimastat is a broad-spectrum matrix metalloprotease inhibitor that functions by binding
to the active site of matrix metalloproteinases where it coordinates the metal ion in the binding
pocket [28,29]. As a water-soluble orally bioavailable matrix metalloproteinase inhibitor [30,31],
marimastat reached phase II and III clinical trials for multiple solid tumor types [32–34], including
pancreatic, lung, breast, colorectal, brain and prostate cancer [35–37]. SVMPs are toxins that are
structurally and functionally homologous to matrix metalloproteinses [38–40]. Like other compounds in
this class of drugs (e.g., batimastat [41]), marimastat is a promising drug candidate for treating snakebite
due to its inhibitory capabilities against SVMP toxins [42,43]. Marimastat was found to effectively
inhibit the hemorrhagic, coagulant and defibrinogenating effects and proteinase activities induced by
Echis ocellatus venom [42]. Dimercaprol, a historical drug approved by the World Health Organization
(WHO) for treatment of heavy metal poisoning [44], contains two metal-chelating thiol groups and has
long been used against arsenic, mercury, gold, lead and antimony intoxication [45–47]. It also represents
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a treatment option for Wilson’s disease in which the body retains copper. Moreover, it has been studied
as a candidate for acrolein detoxification as it can effectively reduce the acrolein concentration in vivo
in murine because of its ability to bind to both the carbon double bond and aldehyde group of acrolein.
The water-soluble, tissue-permeable and licensed metal chelator, 2,3-dimercaptopropane-1-sulfonic
acid (DMPS), is also suitable for treating acute and chronic heavy metal intoxication including lead,
mercury, cadmium and copper [48,49]. It was recently shown that both dimercaprol and DMPS
displayed potential for repurposing as small molecule chelators to treat snake envenoming [20],
most probably by chelating and removing Zn2+ from the active site of Zn2+-dependent SVMPs. Of
the two drugs, DMPS showed highly promising preclinical efficacy when used as an early oral
intervention after envenoming by the SVMP-rich venom of the West African saw-scaled viper (Echis
ocellatus), prior to later antivenom treatment with antivenom [20]. In addition to protecting against
venom-induced lethality, DMPS was also demonstrated to drastically reduce local venom-induced
hemorrhage [20]. Thus, marimastat, dimercaprol and DMPS all represent promising candidates for
drug repurposing as snakebite therapeutics, as they either inhibit SVMPs or chelate the Zn2+ ion
required for SVMP catalysis.
Nanofractionation analytics, which is a recently developed high resolution and high throughput
format of traditional bioassay-guided fractionation, is regarded as an effective method for screening
complex bioactive mixtures such as venoms to rapidly identify and in parallel directly characterize
separated venom toxins biochemically (i.e., for selected bioactivities), by combing reversed-phase
liquid chromatography (RPLC) with parallel post-column bioassays, mass spectrometry (MS)
and proteomics analysis [50–52]. In this paper, the coagulopathic properties of various snakes from
the medically important viper subfamily Viperinae (Echis carinatus, E. ocellatus, Daboia russelii and Bitis
arietans) were evaluated using nanofractionation analytics in combination with a high-throughput
coagulation assay, and the inhibitory capabilities of varespladib, marimastat, dimercaprol and DMPS
against the coagulopathic toxicities of the resulting snake venom fractions revealed. To this end,
bioactivity chromatograms were acquired after fractionation, and parallel obtained mass spectrometry
and proteomics data were used to correlate the observed bioactivities with the identity of the venom
toxins responsible for the observed enzymatic effects. Thus, we assessed the ability of varespladib,
marimastat, dimercaprol and DMPS to neutralize the coagulopathic venom components. The results
indicated that varespladib in combination with heavy metal chelators and/or broad-spectrum
protease inhibitors could be viable first line therapeutic candidates for initial and adjunct treatment
of coagulopathic snakebite envenoming.
2. Experimental
2.1. Chemicals
Water from a Milli-Q Plus system (Millipore, Amsterdam, The Netherlands) was used. Acetronitrile
(ACN) and formic acid (FA) were supplied by Biosolve (Valkenswaard, The Netherlands). Calcium
chloride (CaCl2, dehydrate, ≥99%) was from Sigma-Aldrich (Zwijndrecht, The Netherlands) and was
used to de-citrate plasma to initiate coagulation in the coagulation assay. Phosphate buffered saline
(PBS) was prepared by dissolving PBS tablets (Sigma-Aldrich) in water according to the manufacturer’s
instructions and was stored at −4 ◦C for no longer than one week prior to use. Sodium citrated bovine
plasma was obtained from Biowest (Nuaillé, France) as sterile filtered. The plasma (500 mL bottle) was
defrosted in a warm water bath, and then quickly transferred to 15 mL CentriStarTM tubes (Corning
Science, Reynosa, Mexico). These 15 mL tubes were then immediately re-frozen at −80 ◦C, where they
were stored until use. Venoms were sourced from either wild-caught specimens maintained in, or
historical venom samples stored in, the Herpetarium of the Liverpool School of Tropical Medicine
(LSTM). This facility and its protocols for the expert husbandry of snakes are approved and inspected
by the UK Home Office and the LSTM and University of Liverpool Animal Welfare and Ethical Review
Boards. The venom pools were from vipers with diverse geographical localities, namely: B. arietans
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(Nigeria), D. russelii (Sri Lanka), E. carinatus (India) and E. ocellatus (Nigeria). Note that the Indian E.
carinatus venom was collected from a single specimen that was inadvertently imported to the UK
via a boat shipment of stone, and then rehoused at LSTM on the request of the UK Royal Society
for the Prevention of Cruelty to Animals (RSPCA). Venom solutions were prepared by dissolving
lyophilized venoms into water to a concentration of 5.0± 0.1 mg/mL and were stored at−80 ◦C until use.
The compounds varespladib (A-001), marimastat ((2S,3R)-N4-[(1S)-2,2-Dimethyl-1-[(methylamino)
carbonyl] propyl]-N1,2-dihydroxy-3-(2-methylpropyl) butanedia- mide), dimercaprol
(2,3-Dimercapto-1-propanol) and DMPS (2,3-dimercapto-1-propane-sulfonic acid sodium salt
monohydrate) were purchased from Sigma-Aldrich. They were dissolved in DMSO (≥99.9%,
Sigma-Aldrich) to a concentration of 10 mM and stored at −20 ◦C. Prior to use, these four compounds
were diluted in PBS buffer to the described concentrations.
2.2. Venom Nanofractionation
All venoms were nanofractionated onto transparent 384-well plates, and the plates with fractions
were freeze dried overnight, according to the method described in our previous published papers by
Slagboom et al. [53] and Xie et al. [52,54]. A detailed description can also be found in the Supporting
Information (Section S1).
2.3. Plasma Coagulation Activity Assay
The HTS plasma coagulation assay used in this study was developed by Still et al. [55]. Sample
preparation, assay performed and data analysis were described in our previous published paper by
Still et al. [55], Slagboom et al. [53] and Xie et al. [52,54]. The final concentrations of the inhibitor
solutions used in the coagulation bioassay were 20 µM, 4 µM and 0.8 µM, and in some cases 0.16 µM,
0.032 µM and 0.0064 µM. A detailed description can also be found in the Supporting Information
(Section S2).
2.4. Correlation of Biological Data with MS Data
The corresponding accurate mass(es) and proteomics data for each venom fraction in this study
have already been acquired by Slagboom et al. [53] and as such were correlated with the bioactivity
chromatograms obtained in the current study. For venoms under study in this project that were not
studied by Slagboom et al. [53], the same procedure as previously described [53] was followed to
acquire and process proteomics data on these snake venoms. The UniprotKB database was used to
determine the toxin class and any known functions for the relevant toxins thought to be responsible for
the observed coagulopathic toxicities. For LC separations performed at different times and in different
labs, the retention times of eluting snake venom toxins may differ slightly. The LC-UV chromatograms
(measured at 220 nm, 254 nm and 280 nm), which provided characteristic fingerprint profiles for
each venom fraction, were used to negotiate these retention time shifts. By using the LC-UV data,
the chromatographic bioassay data from this study was correlated with the MS total-ion currents
(TICs), extracted-ion chromatograms (XICs), and proteomics data obtained by Slagboom et al. [53]. In
order to construct useful XICs, MS spectra were extracted from the time frames that correlated with
regions in the chromatograms for each bioactive peak. Then, for all m/z values showing a significant
signal observed in the mass spectra, XICs were plotted. In turn, these XICs were used for matching
with peak retention times of bioactive compounds in the chromatograms. The exact masses matching
the bioactives were tentatively assigned based on matching peak shape and correlation with retention
times in bioassay traces. More specifically, the m/z-values in the MS data were correlated to each
bioactive peak using the accurate monoisotopic masses determined by applying the deconvolution
option in the MS software. For the proteomics data, in-well tryptic digestions were previously
performed by Slagboom et al. [53] on snake venom fractions. These proteomics results were directly
correlated to the coagulopathic activities that were indicated by the bioassay chromatograms.
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3. Results
In this study, a nanofractionation approach was used to evaluate the inhibitory effects
of varespladib, marimastat, dimercaprol and DMPS on the coagulopathic properties of venom
toxins fractionated from a variety of Viperinae snake species. A recently developed low-volume
HTS coagulation bioassay was used to assess the coagulation activities of LC-fractionated venoms
in a 384-well plate format. These coagulopathic activities were correlated to parallel obtained MS
and proteomics data to determine which specific venom toxins were neutralized by the potential
inhibitors. All analyses were performed in at least duplicate to ensure reproducibility, and used venom
concentrations of 1.0 mg/mL.
3.1. Inhibitory Effects of Varespladib, Marimastat, Dimercaprol and DMPS on Echis Venoms
Two geographically distinct saw-scaled viper venoms (genus Echis) were investigated in this study,
specifically from the Indian species E. carinatus and the west African species E. ocellatus. The inhibitory
effects of varespladib, marimastat, dimercaprol and DMPS against the coagulopathic activities
observed for LC fractions of both venoms were investigated in a concentration-dependent fashion
(Figures 1 and 2). Duplicate bioassay chromatograms together with a detailed description of each
coagulopathic peak observed are presented in the Supporting Information (Section S3, Figures S1–S8).
Figure 1 shows the bioassay chromatograms of nanofractionated venom toxins from E. carinatus
in the presence of different concentrations of varespladib, marimastat, dimercaprol and DMPS. In
the venom-only analysis, potent procoagulation activities were observed in the very fast coagulation
chromatogram (22.0–22.9 min) and the slightly/medium increased coagulation chromatogram (21.2–23.1
min and/or 19.9–21.2 min), while anticoagulation activities were observed in the anticoagulation
chromatogram (19.1–19.9 min). Interestingly, the PLA2-inhibitor varespladib inhibited both
the anticoagulation and procoagulation activities, with the exception of one major peak observed
in the slightly/medium increased coagulation chromatogram. In contrast, marimastat, dimercaprol
and DMPS only exerted inhibitory effects on the procoagulation activities of E. carinatus venom.
The anticoagulation activity of E. carinatus venom was fully inhibited by varespladib at a 20
µM concentration, while the very fast procoagulation activity was fully inhibited by varespladib,
dimercaprol and DMPS at a concentration of 4 µM. Marimastat superseded the other small molecules by
fully inhibiting the very fast procoagulation activity at a concentration of 0.16 µM. The slightly/medium
increased coagulation activity was fully inhibited by 0.8 µM marimastat, but a sharp positive peak
(21.7–22.2 min) was still retained following incubation with 20 µM varespladib. Dimercaprol only
inhibited the front peak (21.3–22.1 min) present in the slightly/medium increased coagulation activity
chromatogram, while DMPS inhibited mostly the tailing part (22.2–23.1 min) of this peak at its
highest concentration tested (20 µM). Overall, DMPS was found to be more effective than dimercaprol
in abrogating the procoagulation toxicities of E. carinatus venom. These findings demonstrate
that the tested inhibitors have different specificities, but that marimastat most effectively inhibits
the procoagulant components, and varespladib the anticoagulant components, of E. carinatus venom.
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Figure 1. UV absorbance chromatograms and reconstructed coagulopathic toxicity chromatograms
of nanofraction ted toxins from E. carin tus venom in the presence of different concentrations
of (a) varespladib, (b) marimastat, (c) dimercaprol and (d) DMPS.
Figure 2 shows the bioassay chromatog ams for nanofracti nated toxins from E. ocellatus venom
in the presence of different concentrations of varespladib, marimastat, dimercaprol and DMPS.
In the venom-only analysis, we observed similar results to those obtained for E. carinatus venom;
multiple co-eluting sharp peaks were present in the very fast coagulation chromatogram (25.1–26.2 min),
the slightly/medium increased coagulation chromatogram (25.1–27.1 min) and the anticoagulation
chromatogram (23.4–24.4 min). All peaks decreased in height and width with increasing varespladib
concentrations. The potent negative peak (23.4–24.4 min) in the anticoagulation chromatograms was
fully inhibited by 4 µM varespladib and the later eluting weakly negative peak (25.9 min) by 20 µM
varespladib. While full inhibition of anticoagulation activities was achieved, the procoagulation
activities were not fully inactivated at the highest varespladib concentration tested (20 µM).
However, both the very fast coagulation activity and the slightly/medium increased coagulation activity
were also somewhat reduced by varespladib in a concentration-dependent fashion. Similar findings,
whereby both very fast and slightly/medium increased coagulation were reduced in a concentration
dependent manner but not fully abrogated, were also observed for dimercaprol, although this inhibitor
had no effect on anticoagulant venom activities. Marimastat and DMPS also had no effect on
anticoagulant venom activity, but effectively inhibited the procoagulant actions of E. ocellatus venom.
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Very fast procoagulation activity was fully inhibited at a lower concentration of marimastat (0.16 µM)
than DMPS (20 µM), while slightly/medium increased coagulation activity was fully inhibited by 4 µM
marimastat compared with almost complete inhibition observed when using 20µM DMPS. Thus, similar
to findings with E. carinatus, marimastat exhibited superior inhibition of procoagulant venom activities,
while varespladib was the only inhibitor capable of abrogating anticoagulant venom effects.
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3.2. Inhibitory Effect of Varespladib, arimastat, Dimercaprol and D PS on Daboia russelii Venom
Next, we assessed the inhibitory capability of the same small molecule toxin inhibitors on a Viperinae
snake from a different genus: the Russell’s viper (Daboia russelii), which is a medically-important
species found in south Asia [56–58]. The inhibitory effects of varespladib, marimastat, dimercaprol
and DMPS on the venom of D. russelii are shown in Figure 3. Duplicate bioassay chromatograms for D.
russelii venom analyses can be found in the Supporting Information in Section S4 (Figures S9–S12). For
the venom-only analysis, a strong positive peak was observed for both the very fast coagulation activity
(21.5–22.4 min) and for the slightly/medium increased coagulation activity (21.5–22.8 min). A very
broad and strong negative activity peak (18.6–21.5 min) was also observed, demonstrating potent
anticoagulation activity. In terms of procoagulant venom effects, both very fast and slightly/medium
increased coagulation activities decreased dose-dependently in the presence of varespladib, marimastat
and dimercaprol, although neither varespladib nor dimercaprol could fully neutralize these activities.
However, in line with the earlier findings for the two Echis spp., full neutralization of both types
of procoagulation were observed with marimastat, at 0.8 µM for very fast coagulation activity and at
4 µM for slightly/medium increased coagulation activity. As anticipated, and again in line with findings
observed with Echis spp., neither of the SVMP-inhibitors (marimastat and dimercaprol) abrogated
anticoagulant venom activity. In contrast, varespladib showed potent inhibition of anticoagulation,
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as the broad and potent negative peak (18.6–21.5 min) decreased to only a very minor negative peak
(19.5–20.2 min; 20 µM varespladib) with increasing varespladib concentrations. DMPS showed no
inhibition on both the procoagulant and anticoagulant venom activities of D. russelii at the tested
inhibitor concentrations of 20 µM and 4 µM.
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3.3. Inhibitory Effects of Varespladib and Marimastat on Bitis arietans Venom
The inhibitory effects of varespladib and marimastat on the coagulopathic properties of venom
of the puff adder (B. arietans), which is found widely distributed across sub-Saharan Africa and parts
of the Middle East, are shown in Figure 4. Duplicate bioassay chromatograms for the B. arietans venom
analyses are shown in the Supporting Information in Section S5 (Figures S13 and S14). In the venom-only
analyses, anticoagulation activity was observed as two sharp negative peaks in the bioactivity
chromatograms (16.2–16.7 min and 16.7–17.1 min); however, no procoagulation activity was detected,
which is consistent with previous findings using this venom [59]. Consequently, of the three
SVMP-inhibitors used elsewhere in this study, we only selected marimastat for assessment of toxin
inhibition as a control for the PLA2-inhibitor varespladib. In line with findings from the other Viperinae
species under study, increasing concentrations of varespladib resulted in full inhibition of the two
negative anticoagulation peaks, at concentrations of 0.16 µM and 0.8 µM, respectively. Conversely,
and also in line with our earlier findings, no anticoagulant inhibitory effects were observed with
marimastat, even at concentrations of 20 µM.
3.4. Identification of Coagulopathic Venom Toxins Neutralized by Small Molecule Inhibitors
The MS and proteomics data previously obtained by Slagboom et al. [53] was next used to
assign the venom toxins responsible for the observed coagulation activities tentative identifications.
The resulting identifications are listed in Table 1. In addition, all tentatively identified anticoagulant
PLA2s, including those found in our study not previously described as possessing anticoagulant
properties in the UniprotKB database, are also provided in Table 1. For those toxins for which no exact
mass data could be acquired by LC-MS, only the proteomics mass data retrieved from Mascot searches
are presented in the table.
Based on the results from Figures 1–4 and Table 1, the inhibitory effects of varespladib, marimastat,
dimercaprol and DMPS on individual Viperinae venom toxins were assessed. PLA2 toxins were
identified as toxin components responsible for anticoagulation in all species studied, except for B.
arietans, for which C-Type Lectins (CTLs) were instead identified. All these identified anticoagulant
toxins were fully abrogated by varespladib at various concentrations, as indicated in Table 1. Although
the CTLs identified from B. arietans venom are highly likely to have co-eluted with other venom proteins,
no other anticoagulants were identified from this venom. The toxins identified from the Mascot results
for the procoagulant peaks of E. ocellatus venom included both SVMPs and CTLs. All these identified
toxins were fully abrogated by marimastat at 0.16 µM or by DMPS at 20 µM concentrations. No
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procoagulant toxins could be identified from the Mascot results for E. carinatus and D. russelii venoms,
but given that these bioactivity peaks were fully inhibited by marimastat at low concentrations, it
seems reasonable to speculate that the procoagulant toxins responsible for these activities are mainly
SVMPs. A detailed description of the results discussed here is provided in the Supporting Information
in Section S6.
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There are a number of challenges associated with interpreting the data presented here. In cases
where multiple toxins elute closely, unambiguously assigning single toxins to each detected bioactivity
is challenging. For bioactive compounds that eluted in activity peaks that were only partly inhibited, it
is difficult to critically determine which of them was abrogated. This would require further improving
LC separations under toxin non-denaturating and MS compatible eluent conditions. As a critical note,
it is important to stress that despite venom toxins generally being stable, during chromatography
within the nanofractionation analytics pipeline some venom toxins might have (partly) denatured
and thereby lost their activity.
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Table 1. Correlated MS and proteomics data for associated coagulopathic venom toxins. (Peak retention times are adapted from Figures 1–4; PLA2 = phospholipase
A2; SVMP = Snake Venom Metalloproteinase; CTL = C-Type Lectin).
Species Peak Retention Time (min) Mascot Results Matchingthe Exact Mass
Exact Mass from
MS Data
Exact Mass from
Mascot Data Toxin Class Activity Dose Required for Full Inhibition
E. carinatus
19.1–19.9 PA2A1_ECHCA – 16310 PLA2 Anticoagulant 20 µM varespladib
19.9–23.1 – – – – Procoagulant 0.8 µM marimastat
E. ocellatus
23.4–24.4 PA2A5_ECHOC 13856.138 13856 PLA2 Anticoagulant 4 µM varespladib
25.1–27.1 VM3E2_ECHOC – 69426 SVMP Procoagulant 0.16 µM marimastat/20 µM DMPS
25.1–27.1 VM3E6_ECHOC – 57658 SVMP Procoagulant 0.16 µM marimastat/20 µM DMPS
25.1–27.1 SL1_ECHOC – 16601 CTL Procoagulant 0.16 µM marimastat/20 µM DMPS
25.1–27.1 SL124_ECHOC – 16882 CTL Procoagulant 0.16 µM marimastat/20 µM DMPS
D. russelii
18.6–21.5 PA2B8_DABRR 13587.225 13587 PLA2 Anticoagulant 20 µM varespladib
18.6–21.5 PA2B5_DABRR – 13587 PLA2 Anticoagulant 20 µM varespladib
18.6–21.5 PA2B3_DABRR – 13687 PLA2 Anticoagulant 20 µM varespladib
21.5–22.8 – – – – Procoagulant 4 µM marimastat
B. arietans
16.7–17.1 SLA_BITAR – 14935 CTL Anticoagulant 0.8 µM varespladib
16.7–17.1 SLB_BITAR – 14798 CTL Anticoagulant 0.8 µM varespladib
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4. Discussion
There is an urgent need for stable, effective and affordable snakebite treatments that can be
administered in the field and in rural areas where medical access is limited. Small molecule inhibitors
that specifically target a number of key classes of snake venom toxins have recently gained interest as
candidates for therapeutic alternatives to conventional antivenom.
This study used a high-throughput screening assay combined with LC fractionation and parallel
MS and proteomics data to assess the neutralizing capabilities of a selected number of small molecule
inhibitors and chelators (i.e., varespladib, marimastat, dimercaprol and DMPS). The results of this study
show that these compounds are capable of neutralizing the coagulopathic activities of individual toxins
present in the venoms of a number of Viperinae species. While this is consistent with previous work on
small molecule inhibitors and chelators that exhibit anti-hemorrhagic and anti-procoagulant activities
of snake venoms [9,20,23,42,43,60], here we have studied the relative neutralization potencies of these
small molecules on individual coagulopathic venom toxins. Our findings reveal that varespladib is not
only effective against the activity of anti-coagulant PLA2 toxins, but also shows some inhibitory activity
against procoagulant venom toxins. Varespladib potently and completely inhibited the anticoagulant
activities detected in all venoms, except for D. russelii, for which almost complete inhibition was
observed. Furthermore, varespladib showed some degree of inhibition against procoagulant venom
activities across the various venoms, despite these activities not known to be mediated by PLA2 toxins.
Contrastingly, of the SVMP-inhibitors tested, we demonstrate that their specificities are restricted to
effects on procoagulant venoms toxins, and that the peptidomimetic hydroxamate inhibitor marimastat
outperforms the metal chelators DMPS and dimercaprol in terms of potency. Marimastat potently
inhibited procoagulant activities across the venoms tested and was unsurprisingly ineffective against
anticoagulant venom activities. However, only moderate inhibition was observed for most venoms
with the metal chelators, and no inhibition was found at all for DMPS on D. russelii venom. Neither
DMPS nor dimercaprol inhibited the non-SVMP stimulated anticoagulant venom activities observed
across the venoms.
The advantages of repurposing licensed medicines (e.g., DMPS and dimercaprol) or phase
II-approved drug candidates (e.g., marimastat and varespladib) are that these molecules have
demonstrated safety profiles and thus drug development times could be significantly shortened
as these agents have extensive pharmacokinetic, bioavailability and tolerance data already associated
with them [23,61,62]. The small size of these compounds, compared with conventional antibodies, confer
desirable drug-favorable properties enabling rapid and effective tissue penetration and, depending on
the pharmacokinetics and physicochemical properties of specific inhibitors, often make them amenable
for oral delivery [61,63,64]. Indeed, both varespladib and DMPS have already been demonstrated to
confer preclinical efficacy against snakebite via the oral route [20,63,64]. DMPS is readily absorbed
following oral administration in humans, making it a strong candidate for an oral community-based
therapy [65]; and there are no major side effects or teratogenic effects that have been reported on DMPS
in murine models [66,67]. In contrast, dimercaprol is challenging for clinical use as it currently requires
administration by painful intramuscular injection. Dosing regimens of each inhibitor therefore need
further robust investigation in the context of snakebite in order to help inform lead candidate selection.
Certain small molecule inhibitors have been demonstrated to exhibit broad inhibition of specific
toxin families across diverse medically-important snake species [23,59], as also evidenced here for
the various coagulopathic toxins found across Viperinae venoms. However, these compounds typically
target only a single family of enzymatic toxins (although varespladib seems perhaps capable of targeting
more than one family; see Figures 1a, 2a and 3a), thus presenting a challenge for these molecules to
become standalone therapeutics, as other non-inhibited toxins seem likely to still cause pathology
in snakebite victims. It is therefore more likely that small molecule inhibitors will need to be
combined into therapeutic mixtures, either with other toxin inhibitors or monoclonal antibodies, to
generate snakebite therapeutics capable of neutralizing the most important pathological snake venom
toxin families [26,59,61,62]. Small molecule inhibitors could serve as valuable prehospital snakebite
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treatments to delay the onset of severe envenoming before the arrival of victims to secondary or tertiary
healthcare facilities to receive subsequent therapy (i.e., conventional antivenoms). This is important,
because treatment delays are known to have major detrimental impacts on patient outcomes following
snakebite [68,69]. Indeed, compounds such as varespladib and DMPS are already being explored in
this regard [20,63,64], as they represent promising candidates to be used as bridging therapies for
delaying the major effects of envenomation, and reducing the long time it typically takes rural, isolated,
impoverished snakebite victims to receive any form of treatment.
The many limitations associated with conventional snakebite treatments have resulted in their
weak demand, low availability and poor affordability, despite huge unmet medical need. Small
molecule “toxin inhibitors” offer great potential to rapidly deliver inexpensive, safe and efficacious
interventions in the community soon after a snakebite, prior to subsequent admission to a healthcare
facility. Many small molecule inhibitors also offer superior pharmacokinetics in terms of efficiently
reaching local tissues, such as bite sites, in contrary to antibodies. The findings presented here further
support the exploration of such inhibitors as potential future snakebite treatments.
5. Conclusions
In this study, a recently developed HTS coagulation assay was combined with LC fractionation
and parallel obtained MS and proteomics data to assess the neutralizing potency of several
small molecule inhibitors and chelators (i.e., varespladib, marimastat, dimercaprol and DMPS)
against the coagulopathic activities of individual toxins found in the venoms of Viperinae snakes.
These compounds show great promise for the development of affordable, broad-spectrum, first-aid
and clinical treatment of snakebite. Our data further strengthens recent findings suggesting that small
molecule inhibitors, such as varespladib and marimastat, may have broad, cross-species, neutralizing
capabilities that make them highly amenable for translation into new "generic” snakebite therapeutics.
Given our evidence that both inhibitors have different specificities, our findings further support
the concept that a therapeutic combination consisting of both of these Phase II-approved small molecule
toxin inhibitors [59] show potential as a new broad-spectrum snakebite treatment.
Supplementary Materials: The supporting information related to this article can be found in “Supplementary
Materials: Neutralizing effects of small molecule inhibitors and metal chelators on coagulopathic Viperinae snake venom toxins”.
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